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The activation of muscle-specific gene expression requires the coordinated action of muscle regulatory
proteins and chromatin-remodeling enzymes. Microarray analysis performed in the presence or absence of a
dominant-negative BRG1 ATPase demonstrated that approximately one-third of MyoD-induced genes were
highly dependent on SWI/SNF enzymes. To understand the mechanism of activation, we performed chromatin
immunoprecipitations analyzing the myogenin promoter. We found that H4 hyperacetylation preceded Brg1
binding in a MyoD-dependent manner but that MyoD binding occurred subsequent to H4 modification and
Brg1 interaction. In the absence of functional SWI/SNF enzymes, muscle regulatory proteins did not bind to
the myogenin promoter, thereby providing evidence for SWI/SNF-dependent activator binding. We observed
that the homeodomain factor Pbx1, which cooperates with MyoD to stimulate myogenin expression, is consti-
tutively bound to the myogenin promoter in a SWI/SNF-independent manner, suggesting a two-step mechanism
in which MyoD initially interacts indirectly with the myogenin promoter and attracts chromatin-remodeling
enzymes, which then facilitate direct binding by MyoD and other regulatory proteins.
In eukaryotes, activation of gene expression involves the
ordered assembly of transcriptional regulators, chromatin-
modifying enzymes, RNA polymerase II, and associated gen-
eral transcription factors onto cis-acting elements that are em-
bedded in chromatin. Chromatin-remodeling enzymes play an
integral role in gene activation by perturbing chromatin struc-
ture and making specific loci permissive for transcription. Mo-
lecular analysis of multiple gene activation events suggests that
the temporal recruitment of transcription factors and chroma-
tin-remodeling enzymes is gene specific and dictated by the
interplay between specific activators and local chromatin struc-
ture (1, 52, 55).
Two classes of enzymes have been shown to remodel chro-
matinstructureeitherbycatalyzingcovalentmodificationsofhis-
tones or by hydrolyzing ATP to mobilize nucleosomes. Among
the latter class of enzymes are the SWI/SNF chromatin-remod-
eling complexes. A distinguishing feature of this family is the
presence of a bromodomain in the ATPase subunit, which
promotes interaction with acetylated histones and links the
activities of the two classes of chromatin remodelers in the
regulation of gene expression (22). SWI/SNF enzymes physi-
cally interact with histone acetyltransferases (HATs), histone
deacetylases (HDACs), and methyltransferases, showing the
potential for coordination of chromatin-remodeling activities
(reviewed in reference 53).
Mammalian SWI/SNF chromatin-remodeling enzymes are
multisubunit complexes that contain either the Brg1 or Brm
ATPase subunits and can activate or repress expression of a
subset of genes (39, 53). They function in cell cycle control, and
some of the subunits are tumor suppressors (49). Diverse SWI/
SNF complexes exist that are distinguished by the particular
ATPase, the presence of unique subunits, and tissue-specific
isoforms of common subunits (60, 61). The Brg1- and Brm-
containing complexes are similar biochemically but display dif-
ferent physiological characteristics. In mice, disruption of Brg1
is early embryonic lethal while disruption of Brm has a mild
effect on proliferation (6, 48). Moreover, the two ATPase sub-
units can be associated with different promoters (25, 38).
Mammalian SWI/SNF enzymes have been shown to facili-
tate the binding of TBP and other factors involved in polymer-
ase II (Pol II) preinitiation complex formation and to promote
transcriptional elongation both in vitro and in vivo (5, 11, 24,
33, 52, 55). Multiple models to explain targeting of SWI/SNF
enzymes to specific regulatory sequences exist: interactions
with RNA polymerase II holoenzyme (62), binding of bromo-
domains to acetylated histones (22), and recruitment by se-
quence-specific transcriptional activators (12). In yeast, inter-
action with activators is critical for SWI/SNF function (47), and
in mammalian cells, SWI/SNF components interact with nu-
merous activators, at least some of which likely target SWI/
SNF to specific promoters (8, 11, 18, 26, 30, 32, 35, 46).
During the differentiation of skeletal muscle, the myogenic
basic helix-loop-helix family of regulatory factors (MRFs) het-
erodimerize with ubiquitously present E proteins and bind to
6-bp elements called E boxes. MRFs interact with members of
the myocyte enhancer family (MEF2) of proteins, which bind a
conserved A/T-rich sequence in the regulatory regions of mus-
cle-specific genes, to synergistically activate downstream mus-
cle gene expression (42). Although each MRF can bind to the
* Corresponding author. Mailing address: University of Massachu-
setts Medical School, Department of Cell Biology, 55 Lake Avenue
North, Worcester, MA 01655. Phone: (508) 856-1029. Fax: (508) 856-
5612. E-mail: anthony.imbalzano@umassmed.edu.
† Supplemental material for this article may be found at http://mcb
.asm.org/.
‡ Equal contributors.
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E box with similar affinities, myogenin promotes myogenesis
less efficiently than Myf5 in mouse embryos and is less effective
than MyoD in activating endogenous muscle-specific genes
when introduced into fibroblasts (3, 19). MyoD-mediated gene
activation is associated with chromatin remodeling in the reg-
ulatory regions of muscle-specific genes and depends on a
cysteine-histidine-rich region and a carboxy-terminal region
(16, 19). The carboxy-terminal alpha-helical region of MyoD
that is distinct from that of myogenin specifies the ability to
initiate muscle-specific gene expression (3).
During embryogenesis and skeletal muscle regeneration, it is
the induction of MyoD and/or other MRF proteins that is
critical for commitment to the skeletal muscle lineage, such as
occurs in primary cell cultures and in activated satellite cells
(44, 58). To model events controlling myogenic differentiation
via the induction of MyoD, we have utilized the well-estab-
lished model of MyoD-induced transdifferentiation of fibro-
blast cells, first used to identify MyoD as the regulator of
myogenic differentiation (14).
We previously used this system to establish a role for SWI/
SNF chromatin-remodeling enzymes in MyoD-mediated acti-
vation of two muscle-specific genes and correlated activation of
myogenin transcription with changes in myogenin promoter
chromatin structure (16). We later extended our results to
show that several muscle-specific genes were also inhibited by
dominant-negative SWI/SNF enzymes but that cell cycle con-
trol and expression of key cell cycle regulators, such as p21,
cyclin D3, and Rb, were unaffected during muscle differentia-
tion induced by the different MRFs (17, 50).
To more specifically describe the role that SWI/SNF chro-
matin-remodeling enzymes play in muscle differentiation, we
performed a microarray analysis of cells differentiated by
MyoD in the presence or absence of dominant-negative BRG1
and found that a subset of genes activated by MyoD require
SWI/SNF enzymes. We demonstrate that MyoD induces his-
tone H4 acetylation and localization of Brg1 at the myogenin
promoter; however, stable MyoD binding to the promoter oc-
curs only after chromatin modifications. Expression of domi-
nant-negative BRG1 interferes with MyoD binding to its cog-
nate E box on the myogenin promoter but does not affect
acetylation of histone H4. This raises a paradox: interaction of
SWI/SNF and acetylation of histones at the myogenin pro-
moter require MyoD, but MyoD does not stably bind to the
promoter in the absence of functional SWI/SNF enzyme. To
address this, we demonstrate that the Pbx-1 homeodomain
factor, which cooperates with MyoD to stimulate myogenin
transcription, is constitutively bound to the myogenin pro-
moter in a SWI/SNF-independent manner. This suggests a
novel mechanism by which MyoD interacts with the promoter
indirectly via Pbx-1 and recruits chromatin-remodeling en-
zymes, which then facilitate the binding of MyoD and other
regulators. Demonstration of physical interactions between
Brg1 and MyoD and Brg1 and Pbx support this conclusion.
Models describing the role of SWI/SNF enzymes in the acti-
vation of the myogenin locus that address these and other
recently published data (54) are discussed.
MATERIALS AND METHODS
Cell culture. The B22 cell line inducibly expressing dominant-negative BRG1
(15) was infected with retrovirus expressing MyoD- or MyoD-related regulators
as previously described (14, 16, 17, 50). Briefly, this protocol involves culturing
cells for 3 days in the presence of tetracycline (dominant-negative BRG1 re-
pressed) or in the absence of tetracycline (dominant-negative BRG1 expressed)
and passaging the cells so that 24 h later the cells are at about 50% confluence.
The cells were infected with the retrovirus and incubated for 30 h. A low-serum
differentiation medium was then added to induce myogenic differentiation. The
time at which the differentiation medium was added is referred to as time zero.
Samples were collected at the times indicated (hours) for analysis. Control
samples were mock infected but still subjected to the differentiation protocol and
are labeled “M” or “mock” for mock differentiated. Since the dominant-negative
allele was derived from the human gene (28), capital letters are used throughout
this report when describing the protein produced from this allele. Endogenous
Brg1 in mouse-derived cell lines and the total amount of protein in mouse cells
expressing the dominant-negative human allele are referred to as “Brg1.”
Microarray analysis. For microarray analysis, RNA was prepared with the
RNeasy kit from QIAGEN, and cDNA was generated as described previously
(2). MyoD target genes were identified by comparing cells infected with MyoD-
producing retrovirus (n  3) to control cells (n  3). Data points identified as
unreliable by the scanner software were discarded. Data were normalized using
the Lowess algorithm in the GeneSpring 6.0 analysis package (Silicon Genetics,
Redwood City, CA). Normalized data were then transformed into log2 space. A
heterocedastic t test was performed on each gene. The false discovery rate was
estimated using Storey’s q value (57). The resulting q values were used in
conjunction with the magnitude severalfold change to identify significant genes at
the thresholds described in the text. Brg1-dependent genes were identified in a
similar fashion by comparing cells expressing a dominant-negative BRG1 (n 3)
to control cells (n  3). Estimation of false-discovery rate (q value) for the Brg1
analysis was limited to the 94 genes identified as upregulated by MyoD.
RNA analysis. For reverse transcription (RT)-PCR, RNA was isolated and
reverse transcribed as previously described (17). The cDNA was amplified with
AmpliTaq Gold (Applied Biosystems) with 200 M deoxynucleoside triphos-
phates, 1.5 mM MgCl2, and 0.1 g of each primer as described previously (17).
MyoD and myogenin were amplified for 20 cycles with previously described
primers (59). Hprt was amplified for 20 cycles with previously described primers
(17). Amplification of p21 was for 20 cycles with (5-ACACACAGAGAGAGG
GCTAGG-3) and (5-AGATCCACAGCGATATCCAGAC-3). Flag-BRG1
was amplified for 23 cycles with a primer to the BRG1 coding region (5-GTA
CAAGGACAGCAGCAGTGGA-3) and primer to the Flag coding region (5-
TTTGTCATCGTCGTCCTTGTAGTC-3). [32P]dATP incorporation was de-
tected with PhosphorImager (Molecular Dynamics), and quantification was per-
formed using ImageQuant software.
Antibodies, protein extracts, Western analysis, and immunoprecipitations
(IP). Commercial antibodies utilized were phosphatidylinositol 3-kinase (PI 3-ki-
nase) (06-496; Upstate), Pbx1 (sc-889; Santa Cruz), Mef2 (sc-313; recognizes the
Mef2A, -C, and -D isoforms; Santa Cruz), and MyoD (sc-304; Santa Cruz).
MyoD chromatin immunoprecipitation (ChIP) experiments were confirmed us-
ing an affinity-purified rabbit antibody generated against a fusion protein be-
tween glutathione S-transferase (GST) and full-length MyoD. Polyclonal rabbit
antisera raised against GST fused to a unique portion of BRG1 (15) was used for
all experiments except for the coimmunoprecipitation studies in Fig. 8D and 9A,
which utilized affinity-purified antibody isolated from rat antisera that was gen-
erated against the same GST-BRG1 fusion protein. Flag-tagged proteins were
detected using rabbit antisera against a peptide encoding the Flag epitope or M2
Flag antibody (Sigma).
Isolation of protein and Western analyses were previously described (15). For
coimmunoprecipitations in Fig. 9B, and C, cells were washed three times with
phosphate-buffered saline and lysed with hypotonic buffer (10 mM Tris-HCl, pH
7.5, 10 mM KCl, 3 mM MgCl2, 10 mM NaF, 2 mM sodium orthovanadate,
0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 3 g/ml cytocha-
lasin B, 5 g/ml leupeptin, 2 g/ml pepstatin, and 2 g/ml aprotonin). Cell lysates
were incubated at 4°C for 30 min, homogenized, and centrifuged at 3,000  g for
10 min. Nuclei were then lysed with IP buffer (50 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 200 mM KCl, 0.5 mM EDTA, 1 mM dithiothreitol, 50 mM NaF, 2 mM
sodium orthovanadate, 1 mM -glycerophosphate, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride, 2 g/ml pepstatin, and 2 g/ml aprotonin). Nuclear
extracts were incubated with 200 g/ml DNase I and 10 g/ml RNase A for
30 min at 26°C and then centrifuged at 15,000  g for 15 min. The supernatant
(250 l) was rocked with 2 g of antibody for 12 h at 4°C, followed by the
addition of protein A Sepharose (Amersham) and an additional incubation for
6 h. The beads were washed three times in lysis buffer and eluted with 2% sodium
dodecyl sulfate (SDS) sample buffer. The coimmunoprecipitation experiments in
Fig. 8D and 9A utilized a previously published protocol (43). The coimmuno-
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precipitation of Flag and MyoD (data not shown) utilized a different previously
published protocol (15).
ChIPs. ChIPs were performed using the antibodies listed above as described
previously (52), except that immune complexes were eluted with 0.1 M NaHCO3
and 1% SDS, and following reversal of cross-links, the DNA was purified by
proteinase K digestion followed by phenol-chloroform extraction and ethanol
precipitation. The purified DNA was dissolved in 50 l Tris-EDTA, and 2 l was
used for PCR. For acetylated H4 ChIPs, the dissolved DNA was diluted 20-fold
before PCR. Inputs were 0.5% to 1% of chromatin before immunoprecipitation.
PCRs were performed with QIAGEN HotStart Taq master mix with 2 Ci
[-32P]dATP for 32 cycles. PCR products were run on polyacrylamide gels and
exposed to a PhosphorImager. Band intensities were quantified using the Im-
ageQuant program. Primers to the myogenin regulatory region (34), the immu-
noglobulin H (IgH) enhancer (2), and the -actin promoter (52) were described.
Primers to the p21 promoter region were 5-GTTGGTCTCCATCGGAATA
G-3 and 5-GCCACATACATCTATGAACA-3.
Restriction enzyme accessibility assay. Restriction enzyme accessibility exper-
iments were performed as described previously (16) through purification of the
digested genomic DNA. To visualize the cleaved DNA via PCR, a modified
ligation-mediated PCR protocol was used. One microgram of digested DNA was
ligated to 1 l of 100 mM adaptor as described in reference 7 using Ligation kit
version 2 (Takara). PCR amplification was performed with QIAGEN HotStart
Taq master mix under the following conditions: 94°C for 15 min, followed by 26
cycles of 94°C for 30 s and then 65°C for 60 s, followed by 72°C for 60 s. PCR
products were resolved in a 1.2% Tris-acetate-EDTA-agarose gel and stained
with Sybr Green I. Primers used were the sense primer LM-PCR1, as described
in reference 7, and the antisense primer used for myogenin ChIP (34). Quanti-
fication was performed by densitometry using NIH image 1.62 software.
RESULTS
A subset of MyoD-regulated genes are highly dependent on
the activity of the SWI/SNF complex. Our previous studies
demonstrated that SWI/SNF enzymes are necessary for MyoD
to activate muscle gene transcription but not for MyoD to
stimulate the expression of several cell cycle-regulated genes.
To broadly assess the requirement of SWI/SNF enzymes for
MyoD-mediated gene expression, we used spotted cDNA ex-
pression arrays with approximately 5,400 tiled features repre-
senting 4698 UniGene clusters (UniGene build no. 128, Sep-
tember 2003). We used NIH 3T3 murine fibroblasts that
possess a tetracycline-suppressible, dominant-negative BRG1
allele (15, 28) and compared cells transduced with MyoD to
control cells. Following 24 h in differentiation medium, MyoD
increased the expression of 94 genes and decreased that of 70
genes (q  0.10; change in expression greater than twofold)
(Tables 1 and 2; see also Table S1 in the supplemental mate-
rial). These 94 genes (represented by 96 array features) were
analyzed for their dependence on a functional Brg1-based
SWI/SNF complex. In the presence of dominant-negative
BRG1, 29 genes did not achieve full activation by MyoD, as
determined by statistical criteria (q  0.05) and a twofold or
more decrease in expression level (Table 1; see also Table S1
in the supplemental material). Some of the genes regulated by
MyoD that were not dependent on SWI/SNF activity, such as
pRb, cyclin D3, and p21 (17) (Table 2), are expressed prior to
MyoD induction, whereas others, such as the beta and gamma
subunits of the nicotinic acetylcholine receptor, are not ex-
pressed in fibroblasts and are induced by MyoD even in the
presence of dominant-negative BRG1 (Table 2). We had pre-
viously documented that MyoD could activate cell cycle-regu-
lated genes in the absence of functional SWI/SNF enzymes;
however, the ability of MyoD to induce the expression of some
previously silent loci in the absence of SWI/SNF function was
not previously recognized. Of the 70 genes repressed by MyoD,
only five were derepressed more than twofold in the presence
TABLE 1. Selected MyoD-induced genes affected twofold or more by dominant-negative BRG1
GenBank no. UniGene no. Name of gene product
Fold change
MyoD/BRG1a Dom. Neg. BRG1b
NM_009394 Mm.1716 Troponin C2, fast 307.3 	10.1
NM_011620 Mm.14546 Troponin T3, skeletal, fast 225.7 	8.4
NM_011619 Mm.247470 Troponin T2, cardiac 219.3 	2.4
NM_016754 Mm.14526 Myosin light chain, phosphorylatable, fast skeletal muscle 209.9 	5.8
X15784 Mm.16528 Myogenin 186.3 	10.7
M38129 Mm.340090 Myosin, heavy polypeptide 3, skeletal muscle, embryonic 90.7 	19.1
X15784 Mm.16528 Myogenin 83.4 	7.3
NM_009405 Mm.39469 Troponin 1, skeletal, fast 2 71.2 	7.4
AL385643 Mm.269621 Myosin binding protein H 19.8 	10.4
Al324268 Mm.2375 Creatine kinase, muscle 16.6 	8.3
M19436 Mm.247636 Myosin, light polypeptide 4, alkali; atrial, embryonic 12.9 	4.1
Al324023 Mm.1000 Myosin, light polypeptide 1, alkali; atrial, embryonic 9.6 	3.6
NM_010518 Mm.309617 Insulin-like growth factor binding protein 5 9.1 	2.0
Al324248 Mm.35134 ATPase, Ca2 transporting, cardiac muscle, fast twitch 1 8.6 	4.1
Al414541 Mm.24059 Schwannomin-interacting protein 1 6 	2.2
Al661474 Mm.7342 PDZ and LIM domain 3 4.3 	2.2
Al325234 Mm.251322 Enolase 3, beta muscle 7.4 	2.5
NM_009668 Mm.4383 Bridging integrator 1 3.8 	2.3
Al604795 Mm.220982 Dysferlin 3.3 	2.1
Al326773 Mm.39968 Histidine-rich calcium binding protein 2.9 	2.5
Al447277 Mm.295105 (PTPRF), interacting protein (liprin), alpha 4 2.9 	2.1
M12866 Mm.214950 Actin, alpha 1, skeletal muscle 2.9 	2.2
Al430815 Mm.29475 CK2-interacting protein 1 2.8 	2
Al325457 Mm.22513 Kinesin family member C3 2.8 	2.3
Al385590 Mm.275654 Glycogen synthase 3, brain 2.3 	2.8
Al326236 Mm.31646 Actin-like 6 	2.2 	2.1
a Induction of gene expression after 24 h of differentiation with MyoD in the absence of dominant-negative BRG1.
b Fold change in induction after 24 h of differentiation with MyoD when dominant-negative BRG1 is expressed.
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of dominant-negative BRG1, suggesting that SWI/SNF en-
zymes play a limited role in MyoD-mediated gene repression
(see Table S1 in the supplemental material).
Despite the fact that only a subset of MyoD-regulated genes
are highly dependent on SWI/SNF enzymes based on a sever-
alfold change and statistical criteria, the expression of most of
the MyoD-regulated genes was reduced in the absence of an
active SWI/SNF complex. Graphing the log of the ratio of gene
expression in the presence or absence of dominant-negative
BRG1 revealed a distribution centered on zero for all the
genes in the array (median ratio in log2 space is 	0.02) (Fig.
1A), indicating that SWI/SNF activity does not globally alter
gene expression. In contrast, limiting the analysis to the 94
genes regulated by MyoD shifted the center of the distribution
below zero (median ratio in log2 space is 	0.56), indicat-
ing that MyoD-regulated genes require SWI/SNF activity to
achieve their full level of expression more than the typical gene
spotted on the array (Fig. 1B). This is not solely due to the
contribution of the highly SWI/SNF-dependent MyoD targets,
because limiting the analysis to the MyoD target genes that
were not identified as Brg1 dependent by the statistical criteria
also provides a skewed histogram, with a median ratio of
	0.23, as opposed to the median near 0 for all genes (Fig. 1B,
double-headed arrow). The subset of genes that is highly de-
pendent on SWI/SNF for MyoD activation is represented in
the asymmetric tail of genes with negative ratios (29 genes
demonstrate more than a twofold decrease in expression in the
presence of dominant-negative BRG1; see Fig. 1B, unfilled
bars). Therefore, the array data reveal a modest global depen-
dence of MyoD-regulated genes on SWI/SNF enzymes and a
more profound dependence for approximately one-third of the
MyoD-regulated genes tested.
To better document the role of SWI/SNF enzymes during
the induction of the subset of muscle marker genes that are
highly dependent on these chromatin remodelers for MyoD-
mediated gene activation, we elected to focus on the myogenin
gene. Previously, we demonstrated that myogenin activation by
MyoD or other members of the MyoD family of muscle regu-
TABLE 2. Selected MyoD-induced genes affected twofold or less by dominant-negative BRG1
GenBank no. UniGene no. Name of gene product
Fold change
MyoD/BRG1a Dom. Neg. BRG1b
NM_010866 Mm.1526 Myogenic differentiation 1c 42.7 1.1
M30514 Mm.2810 Cholinergic receptor, nicotinic, gamma polypeptide 19.6 	1
Al427434 Mm.256342 Kinesin family member 5C 12.3 1.8
Al385656 Mm.4583 Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 10 	1.9
M14537 Mm.86425 Cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 8.6 	1.2
NM_013597.2 Mm.132788 Myocyte enhancer factor 2A 7.5 	1.7
Al323806 Mm.195663 Cyclin-dependent kinase inhibitor 1A (p21) 7.2 	1.5
Al894122 Mm.4261 Kangai 1 (suppression of tumorigenicity 6, prostate) 7.1 	1.2
Al326893 Mm.280029 Hairy and enhancer of split 6 (Drosophila) 5.5 1.0
Al323835 Mm.273862 Purinergic receptor (family A, group 5) 4.9 	1.0
NM_009029 Mm.273862 Purinergic receptor (family A, group 5) 4.8 	1.2
Al324186 Mm.297976 Glypican 1 4.7 	1.4
NM_011817 Mm.281298 Growth arrest and DNA-damage-inducible 45 gamma 4.2 1.1
Al451932 Mm.4081 Runt-related transcription factor 1 4.0 	1.8
Al450263 Mm.333762 Lectin, galactose binding, soluble 4 3.8 1.3
Al415710 Mm.25559 Serine/threonine kinase 17b (apoptosis-inducing) 3.5 	1.9
Al426448 Mm.28683 Transferrin receptor 3.4 	1.5
Al528676 Mm.347398 B-cell leukemia/lymphoma 6 3.1 	1.8
NM_011484 Mm.273174 Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2.9 	1.2
Al428484 Mm.30841 Calcium channel, voltage-dependent, alpha2/delta subunit 1 2.9 	1.2
NM_007483 Mm.687 ras homolog gene family, member B 2.9 	1.6
NM_010722 Mm.7362 Lamin B2 2.8 1.2
Al326964 Mm.3862 Insulin-like growth factor 2 2.8 	1.9
Al450264 Mm.180750 Prion protein dublet 2.8 	1.7
AB025099 Mm.30262 Kruppel-like factor 5 2.8 	1.5
Al326148 Mm.289832 Proteasome (prosome, macropain) 26S subunit, ATPase 3 2.7 	1.3
Al429452 Mm.280805 Huntingtin-interacting protein 1 2.6 1.1
Al451071 Mm.25594 Protein kinase, cAMP dependent regulatory, type II beta 2.5 1.3
Al425917 Mm.29495 CUG triplet repeat, RNA binding protein 1 2.5 	1.0
Al326978 Mm.280103 ATPase, Na/K transporting, alpha 1 polypeptide 2.5 	1.2
Al573376 Mm.22673 Fc receptor, IgE, high-effinity I, gamma polypeptide 2.5 	1.3
Al414367 Mm.65906 Pre-B-cell leukemia transcription factor-interacting protein 1 2.5 1.2
Al447937 Mm.12863 Heparan sulfate 2-O-sulfotransferase 1 2.5 	1.2
Al324262 Mm.294083 Annexin A11 2.5 	1.4
Al449015 Mm.206218 Histone deacetylase 11 2.4 1.0
Al324952 Mm.289131 3-Hydroxy-3-methylglutaryl-coenzyme A synthase 2 2.4 	1.1
Al323871 Mm.246520 Cyclin D3 2.3 	1.1
Al894225 Mm.19016 Drebrin 1 2.3 	1.1
Al449069 Mm.6529 Dystrophia myotonica kinase, B15 2.3 	1.3
U22445 Mm.177194 Thymoma viral proto-oncogene 2 2.2 	1.5
Al428800 Mm.206779 Cytoplasmic polyadenylation element binding protein 3 2.2 	1.3
Al325922 Mm.276826 Cofilin 2, muscle 2.2 1.3
a Induction of gene expression after 24 h of differentiation with MyoD in the absence of dominant-negative BRG1.
b Fold change in induction after 24 h of differentiation with MyoD when dominant-negative BRG1 is expressed.
c Exogenously expressed from retroviral vector.
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latory proteins failed in the presence of dominant-negative
SWI/SNF enzymes and showed that SWI/SNF-dependent myo-
genin activation correlated with a SWI/SNF-dependent in-
crease in promoter accessibility at the endogenous myogenin
locus (16, 17, 50). We therefore sought to build on this base of
knowledge by temporally examining the interplay of SWI/SNF
enzymes and myogenic transcription factors during myogenin
activation.
Kinetics of myogenin activation during MyoD-mediated dif-
ferentiation. We first performed a temporal analysis of gene
expression. We infected cells with a MyoD-expressing retrovi-
rus for 30 h, induced differentiation by adding a low-serum
differentiation medium at time zero, and took samples for
analysis at the indicated time points. RT-PCR analysis showed
that MyoD was expressed 8 h before the addition of differen-
tiation medium and remained constant throughout differenti-
ation in the presence and absence of tetracycline (Fig. 2A). A
slight increase in the amount of myogenin mRNA was appar-
ent in the hours following addition of the differentiation me-
dium, with a significant increase in mRNA levels after 8 h of
differentiation. Myogenin expression was inhibited by domi-
nant-negative BRG1 at all time points (Fig. 2A and B). Induc-
tion of p21 cyclin-dependent kinase inhibitor occurred 4 h after
differentiation and continued to increase but was less than two-
fold affected by dominant-negative BRG1, in agreement with
previous work (17, 50) and with the microarray results (Table 2).
The levels of Brg1 and Brm as well as the levels of Flag-
tagged dominant-negative BRG1 remained constant during
MyoD-mediated differentiation (Fig. 2C). Interestingly, overall
expression of Brg1 did not change when dominant-negative
BRG1 was present, demonstrating that induction of dominant-
negative BRG1 did not result in overexpression of total Brg1.
FIG. 1. (A) Histogram of the expression ratio in cells expressing
dominant-negative BRG1 (BRG1	) to nonexpressing cells (BRG1)
for the 4,282 array features that reported reliable data. The median
value in log2 space is 	0.02. (B) Histogram of the BRG1	/BRG1
expression ratio for the 94 genes upregulated by MyoD. Hollow boxes
indicate the 29 genes identified as strongly BRG1 dependent at the
twofold change (q  0.05) threshold. The single-headed arrow indi-
cates the median ratio for all 94 MyoD-dependent genes (	0.56). The
double-headed arrow indicates the median for the 65 genes not iden-
tified as strongly BRG1 dependent (	0.23).
FIG. 2. (A) Time course of myogenin, p21, and ectopic MyoD
expression during differentiation. Cells expressing or not expressing
dominant-negative flag-tagged BRG1 were infected with retrovirus
containing MyoD. Thirty hours later, differentiation was initiated by
replacement of the medium with a low-serum differentiation medium
(time zero). mRNA levels of each gene were examined at the indicated
time points by RT-PCR. The 	8 time point is 8 h prior to addition of
differentiation medium. A titration of twofold dilutions of cDNA
shows the linearity of the PCRs. The 36-h time point, plus-tetracycline
(Tet) sample, was used for all titrations except for Flag-tagged domi-
nant-negative BRG1, which was amplified with the 36-h, minus-tetra-
cycline sample. (B) Quantification of mRNA levels observed in panel
A. Fold induction was defined as the ratio of myogenin or p21 levels in
a given sample relative to the levels of Hprt in the same sample and
standardized to the 	8-h time point. (C) Time course of dominant-
negative BRG1, total Brg1, and Brm protein levels during differenti-
ation. A Western blot was performed with protein extracts isolated at
the indicated time points. “Mock” refers to the samples that were not
infected with the MyoD-encoding retrovirus but were instead mock
infected, subjected to the same differentiation protocol, and harvested
24 h after the addition of differentiation medium.
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This effectively eliminates the possibility that expression of
dominant-negative BRG1 results in nonspecific effects on tran-
scription and promoter localization due to overexpression. It
also suggests that a compensating mechanism exists for regu-
lating Brg1 levels in cells. Tight regulation and compensation
for levels of the SWI/SNF enzyme subunits Brm, Baf57, and
Ini1 have previously been demonstrated (9, 20, 48).
We then examined changes in nuclease accessibility at the
endogenous myogenin promoter. Previously, we reported a dif-
ferentiation-dependent increase in restriction enzyme accessi-
bility at a PvuII site 370 bp upstream of the transcription ini-
tiation site and showed that the change in accessibility required
SWI/SNF chromatin remodeling activity (16). We monitored
the change in accessibility at this site as a function of time of dif-
ferentiation, using a modified protocol in which a linker DNA
was ligated to the purified, digested genomic DNA fragments
followed by PCR amplification to permit visualization of the
cleaved DNA (see Materials and Methods). We observed a
small but noticeable increase in accessibility at 4 h postdiffer-
entiation and a continued increase in accessibility as differen-
tiation proceeded (Fig. 3). Thus, the change in promoter acces-
sibility precedes the onset of myogenin mRNA accumulation.
Histone acetylation and recruitment of SWI/SNF to muscle-
specific promoters occurs in response to MyoD-mediated dif-
ferentiation. We previously showed that chromatin remodeling
is inhibited by dominant-negative BRG1 in MyoD-differenti-
ated cells (16). Upon differentiation, hyperacetylation of his-
tones surrounding the MyoD and Mef2 binding sites of several
muscle-specific genes has been reported (34, 37). To determine
whether dominant-negative BRG1 inhibits acetylation of his-
tone H4, we differentiated cells with MyoD in the presence or
absence of tetracycline, cultured the cells in differentiation
media for 36 h, and then performed ChIP analysis. Figure 4
shows that muscle differentiation resulted in histone H4 hy-
peracetylation at the myogenin promoter and that H4 hyper-
acetylation was not inhibited by dominant-negative BRG1 in
cells differentiated in the absence of tetracycline. This indicates
that hyperacetylation of histone H4 occurs independently of
SWI/SNF chromatin remodeling. We also looked at the acet-
ylation status of the p21 promoter, because p21 expression is
up-regulated during muscle differentiation but is not depen-
dent on functional SWI/SNF chromatin-remodeling enzymes
(17). We found a high level of histone acetylation at the p21
promoter in both mock-differentiated and differentiated cells
compared to results with the silent IgH enhancer (Fig. 4B and
C). This substantiates our previous conjecture that in fibro-
blasts, the promoters of genes that are constitutively expressed
at low levels or that are regulated in a cell cycle-dependent
manner may not require extensive chromatin remodeling.
To show that Brg1 is directly acting at these regulatory re-
gions, we performed ChIP analysis with a BRG1 antibody and
an antibody to the Flag epitope to detect epitope-tagged dom-
inant-negative BRG1. We found that Brg1 was recruited to the
myogenin promoter upon differentiation in the presence and
absence of tetracycline and that Flag-tagged dominant-nega-
tive BRG1 could also be localized to these regions in differ-
entiated cells (Fig. 4B and C). Surprisingly, although p21 up-
regulation during muscle differentiation is not appreciably
affected by dominant-negative BRG1 (17, 50) (Fig. 2A and B
and Table 2), Brg1 was localized to the promoter region both
in mock-differentiated and differentiated cells (Fig. 4B). SWI/
SNF enzymes have been reported to play a direct role in the
regulation of p21 transcription in other cell types that are
actively proliferating; therefore, the requirement for SWI/SNF
enzymes may be cell type or cell cycle stage specific (23, 27). In
fibroblasts, the local chromatin structure on the p21 promoter
may not require extensive chromatin remodeling by SWI/SNF
enzymes during muscle differentiation and/or there may be
redundant mechanisms for achieving remodeling. Thus, SWI/
SNF enzymes likely contribute to p21 expression but are not
required as they are for many of the muscle-specific genes.
MRF and Mef2 association with muscle-specific promoters
at an endpoint of muscle differentiation is inhibited by domi-
nant-negative BRG1. It is generally thought that transcrip-
FIG. 3. Restriction enzyme accessibility increases at the endoge-
nous myogenin promoter as a function of MyoD-induced differentia-
tion and requires functional Brg1 based-SWI/SNF enzymes. Nuclei
were isolated from cells that were differentiated in the presence or
absence of tetracycline at the indicated time points or from cells that
were mock differentiated (M) in the presence or absence of tetracy-
cline. The mock-differentiated cells were not infected with the MyoD-
encoding retrovirus but were subjected to the differentiation protocol
for 32 h. (A) A modified LM-PCR protocol (see Materials and Meth-
ods) was utilized to visualize cleaved genomic DNA isolated from
nuclei digested with PvuII, which cleaves the myogenin promoter at
	370 relative to the start site of transcription. The PCR product was
visualized by Sybr Green I staining, and an inverse image is shown. To
monitor the input DNA, 10% of the amount of purified, cleaved DNA
that was used for ligation-mediated PCR was used to amplify the
sequences between 	143 and 	5 of the myogenin promoter, which
contain no PvuII site. (B) Quantification of the change in nuclease
accessibility at the myogenin promoter. The relative values for each
time point were normalized to input and graphed relative to the value
obtained for cleavage in the mock-differentiated, plus-tetracycline
[Tet()] sample, which was arbitrarily set at 1.0. Each value is the
mean 
 standard deviation from three independent experiments.
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tional regulators play a critical role in targeting of chromatin-
remodeling complexes to specific promoters. Both MyoD and
Mef2 have been shown to interact with HATs and/or HDACs
(41). We therefore conducted ChIP analysis of cells following
differentiation in the presence or absence of dominant-nega-
tive BRG1 using antibodies to MyoD, myogenin, and Mef2 to
localize these proteins on the myogenin promoter. Figure 5A
and B shows that MyoD, myogenin, and Mef2 were associated
with the myogenin promoter in differentiated cells with wild-
type Brg1 activity; however, there was marked inhibition of
binding by all three proteins when dominant-negative BRG1
was expressed. No binding of MyoD, myogenin, or Mef2 was
observed on the -actin promoter or the inactive IgH en-
hancer, which contains a consensus E box. Since MyoD and
myogenin are structurally similar, we infected separate NIH
3T3 cell cultures with retroviruses encoding one of each of the
MyoD family of myogenic regulators (50) to demonstrate that
the MyoD and myogenin antibodies do not cross-react (Fig.
5C). This indicates that both MyoD and myogenin can occupy
the myogenin promoter.
We have previously shown that ectopic expression of MyoD
is not affected by dominant-negative BRG1 (16) (Fig. 1; see
also Fig. 8A), while endogenous myogenin induction is pro-
foundly inhibited and Mef2 induction is inhibited to a lesser
extent (16, 17) (Fig. 2A and B; see also Fig. 9). Thus, the ob-
served inhibition of myogenin and Mef2 binding in the pres-
ence of dominant-negative BRG1 is at least in part due to
reduced levels of these proteins. However, this is not the case
FIG. 4. Brg1 and hyperacetylated H4 are associated with the myo-
genin promoter. (A) A schematic diagram indicating the regions of the
myogenin and p21 promoters and the IgH enhancer that were ampli-
fied. Arrows indicate the location and direction of primers used for
amplification. The approximate locations of transcription factor bind-
ing sites are indicated. (B) Chromatin immunoprecipitations were per-
formed with antisera against BRG1, Flag, or tetra-acetylated histone
H4 (AcH4) or with no antibody (No Ab) on mock-differentiated (	) or
MyoD-differentiated () samples that had been cultured in the pres-
ence or absence of tetracycline (tet) and that were harvested for
analysis 36 h after the onset of differentiation. PCR amplification of
1% of the input DNA is shown on the left. A twofold titration of input
DNA using the undifferentiated, plus-tetracycline sample was per-
formed (far right) to show that the PCR was in the linear range. (C and
D) Quantification of the levels of hyperacetylated H4, Brg1, and Flag-
tagged dominant-negative BRG1 present on the myogenin and p21
promoters by ChIP analysis. Band intensities in each lane were nor-
malized to input. Induction relative to the plus-tetracycline, mock-
differentiated sample is shown for hyperacetylated H4 and Brg1. In-
duction relative to the minus-tetracycline, mock-differentiated sample
is shown for Flag-tagged dominant-negative BRG1. The data reflect
the means 
 standard deviations from three to four independent
experiments, except for the levels of Brg1 and Flag-tagged dominant-
negative Brg1 on the p21 promoter, which reflect the average values
from two independent experiments.
FIG. 5. Binding of muscle regulatory proteins to the myogenin
promoter is inhibited by dominant-negative BRG1. (A) Chromatin
immunoprecipitations were performed with antisera against MyoD,
myogenin, or Mef2 or with no antibody (No Ab) on MyoD-differen-
tiated samples that had been cultured in the presence or absence of
tetracycline (tet) and that were harvested for analysis 36 h after the
onset of differentiation. PCR amplification of 0.5% of the input DNA
is shown on the left. A twofold titration of input DNA using the
undifferentiated, plus-tetracycline sample was performed (far right) to
show that the PCR was in the linear range. (B) Quantification of the
level of MyoD, myogenin, or Mef2 present on the myogenin promoter
by ChIP analysis. Band intensities in each lane were normalized to
input. The decrease in promoter association due to the expression of
dominant-negative BRG1 is expressed relative to the differentiated,
plus-tetracycline sample, which was set at 1.0. The data reflect the
mean 
 standard deviation from three independent experiments.
(C) MyoD and myogenin antisera do not cross-react. Protein extracts
from C2C12 myotubes or NIH 3T3 cells infected with MyoD, myoge-
nin-, MRF4-, or Myf5-containing retrovirus or the empty retroviral
vector (pBABE) were run on an SDS-polyacrylamide gel, blotted, and
probed with either anti-MyoD or antimyogenin antiserum.
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for the inhibition of MyoD binding caused by dominant-neg-
ative BRG1. The inhibition of MyoD association with the myo-
genin promoter suggests that SWI/SNF enzyme function is
required to form a stable DNA binding complex within chro-
matin and does not support the idea that MyoD stably bound
to chromatin directly targets Brg1-containing SWI/SNF en-
zymes to muscle-specific promoters.
Activation of p21 expression is critical for muscle differen-
tiation and is promoted by MyoD (21, 45, 63). Although there
are potential E boxes in the upstream region of p21, we did not
detect significant levels of MyoD, myogenin, or Mef2 binding
on the endogenous p21 upstream region at the end of the
differentiation protocol by ChIP analysis (Fig. 5A), suggesting
that MyoD activates p21 expression by an indirect mechanism
and/or that our ChIP experiments do not detect an indirect
association of MyoD with the p21 promoter through protein-
protein interactions as previously was demonstrated for MyoD
and CREB on the Rb promoter (36).
Kinetics of myogenin promoter interactions during MyoD-
mediated differentiation. To determine how promoter interac-
tions might influence the timing of myogenin expression, we
performed ChIPs over the time course of differentiation (Fig.
6A). We found that Brg1 was recruited to the promoter 6 h
before addition of differentiation medium and remained pres-
ent throughout differentiation. Dominant-negative BRG1 was
also present on the myogenin promoter, as seen by the ChIPs
of Flag-tagged dominant-negative BRG1. Likewise, histone
H4 on the myogenin promoter was hyperacetylated by 6 h prior
to differentiation and was unaffected by dominant-negative
BRG1. This indicates that chromatin-remodeling enzymes are
associated with the myogenin promoter prior to significant
gene expression and suggests that additional chromatin mod-
ifications may occur before activation of transcription. On the
p21 promoter, recruitment of Brg1 and acetylation of histone
H4 did not change significantly as a function of muscle differ-
entiation, and neither was affected by expression of dominant-
FIG. 6. Brg1 and acetylated H4 associate with the myogenin promoter prior to stable binding of MyoD and Mef2. Shown is a time course of
histone H4 acetylation, total Brg1, dominant-negative BRG1, MyoD, and Mef2 association with (A) the myogenin promoter, (B) the p21 promoter,
and (C) the IgH enhancer as measured by ChIP during a time course of differentiation induced by MyoD in the presence or absence of tetracycline
(tet). M indicates samples that were mock differentiated for 24 h. “No Ab” indicates ChIP reactions performed in the absence of antibody. Linearity
of the PCRs was demonstrated by twofold titrations of input DNA using the mock-differentiated, plus-tetracycline sample. PCR amplification of
1% of the input DNA is shown. (D and E) Quantification of the levels of acetylated H4, Brg1, MyoD, or Mef2 present on the myogenin promoter
(D) or on the p21 promoter (E) by ChIP analysis. Band intensities in each lane were normalized to input. Induction relative to the plus-tetracycline,
mock-differentiated sample is shown. The data reflect the average value from two independent experiments.
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negative BRG1 (Fig. 6B). Neither Brg1 nor hyperacetylated
H4 was present on the inactive IgH enhancer (Fig. 6C).
ChIPs with the MyoD antibody showed that MyoD was
bound at 8, 12, and 24 h after the addition of differentiation
medium but not if the cells were differentiated in the presence
of dominant-negative BRG1. Stable association of MyoD with
the myogenin promoter was dependent on functional SWI/
SNF enzymes and occurred just prior to the significant increase
in myogenin gene expression after 8 h postdifferentiation (Fig.
2A and B and 6A). These results were confirmed with a dif-
ferent antibody against MyoD (data not shown). ChIP exper-
iments to detect Mef2 binding on the promoter generated
similar results (Fig. 6A). In contrast, amplification of the p21
promoter or IgH enhancer showed no or minimal interaction
of MyoD with these sequences (Fig. 6B and C).
These results indicate that histone hyperacetylation and re-
cruitment of Brg1 occur early during the differentiation pro-
cess and well prior to stable binding of MyoD to the myogenin
promoter. Bromodomains of chromatin-remodeling enzymes
display high affinity for acetylated histones, and histone acet-
ylation can facilitate the recruitment of SWI/SNF enzymes
(22). To determine whether histone acetylation occurs prior to
the recruitment of Brg1 to the myogenin promoter, we con-
ducted ChIPs at earlier time points. Figure 7A shows that
histone H4 hyperacetylation could first be detected 12 h after
infection with the MyoD retrovirus or 18 h before addition of
the differentiation medium at time zero, whereas recruitment
of Brg1 occurred 19 h after retroviral infection or 11 h before
addition of differentiation media. These results demonstrate
that histone H4 acetylation coincides with the appearance of
detectable levels of MyoD protein (Fig. 7B and C) and pre-
cedes the recruitment of Brg1, suggesting that histone acety-
lation facilitates the interaction of SWI/SNF complexes with
the myogenin promoter. Thus, during MyoD-directed differ-
entiation, the myogenin promoter becomes hyperacetylated on
H4 prior to Brg1 recruitment. Although these initial events
depend on MyoD, they precede stable binding of MyoD to the
promoter in a SWI/SNF-dependent manner, raising the ques-
tion of how the chromatin-remodeling enzymes become spe-
cifically localized to the promoter.
Pbx1 is constitutively associated with the myogenin pro-
moter and participates in the recruitment of chromatin-re-
modeling complexes. Recent studies suggest that MyoD is re-
cruited to the myogenin promoter through interaction of its
cysteine/histidine and helix 3 regions with a homeodomain
protein complex containing Pbx and Meis that is constitutively
bound to the myogenin promoter (4). If targeting of chroma-
tin-remodeling enzymes occurs via the Pbx-Meis site, one
would predict that factor binding to this site would be inde-
pendent of chromatin-remodeling activities. To address this
question, we performed ChIPs with an antibody against Pbx1
during a time course of differentiation in the presence or ab-
sence of dominant-negative BRG1. Western analyses showed
that Pbx1 levels did not change during MyoD-mediated muscle
differentiation and were not affected by dominant-negative
BRG1 (Fig. 8A). Figure 8B and C shows that, as previously
reported, Pbx1 was constitutively associated with the myogenin
promoter (4). Significantly, association of Pbx1 was not affect-
ed by dominant-negative BRG1; thus, Pbx1 potentially plays a
role in the recruitment of Brg1 and other chromatin-remodel-
ing activities to the myogenin promoter, perhaps via a direct
interaction or via indirect recruitment through MyoD bound to
the Pbx/Meis complex.
The previously published studies indicate that MyoD and
Pbx1 interact at the myogenin promoter both in vivo and in
vitro (4, 29). We therefore tested whether endogenous Brg1
and endogenous Pbx1 can physically interact before the onset
of stable MyoD binding and the initiation of myogenin tran-
scription. Figure 8D demonstrates that Brg1 from nuclear ex-
tracts prepared from differentiated cells coimmunoprecipi-
tated with Pbx1 at the onset of differentiation and at 4 h
postdifferentiation. The interaction was not observed in mock-
differentiated cells and was not appreciably affected by the
expression of dominant-negative BRG1 in the cells, indicating
that the mutant BRG1 molecule also likely interacts with Pbx1.
The results reveal that a specific Brg1-Pbx1 interaction occurs
in the presence of MyoD, thereby supporting the idea that
SWI/SNF enzymes are targeted by a MyoD-Pbx1 complex that
is present on the promoter prior to the stable interaction of
MyoD with the chromatin.
FIG. 7. (A) Histone H4 hyperacetylation precedes the binding of
Brg1 at the myogenin promoter. Shown is a time course of histone H4
hyperacetylation and Brg1 association with the myogenin promoter.
Cells were grown in the presence or absence of tetracycline (Tet),
infected or not with MyoD-encoding retrovirus, and harvested for
ChIP at the indicated times prior to the addition of differentiation
medium. Time points are also indicated as hours following retroviral
infection. Association with the IgH enhancer is presented as a control.
One percent of the input is shown. (B) Western analysis of MyoD and
Mef2 protein present at the indicated times prior to addition of dif-
ferentiation medium. Anti-Flag antiserum was used to document the
presence of the Flag-tagged dominant-negative BRG1. PI 3-kinase
(PI3K) is shown as a loading control. (C) Quantification of the levels
of acetylated H4 and Brg1 present on the myogenin promoter by ChIP
analysis. Band intensities in each lane were normalized to input. In-
duction of levels of association is presented relative to the plus-tetra-
cycline, mock-differentiated sample. The data reflect the average value
from two independent experiments.
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Brg1 interacts with MyoD and Mef2 in differentiated cells.
To further examine mechanisms for recruitment of SWI/SNF
enzymes to the myogenin promoter, we investigated whether
endogenous Brg1 could stably associate with MyoD and/or
Mef2 in differentiating cells. Pulldown of Brg1 from differen-
tiated cell nuclear extracts demonstrated that MyoD and Brg1
could be coimmunoprecipitated at the onset of differentiated
as well as at later times and that MyoD was capable of inter-
acting with the dominant-negative Brg1 protein as well (Fig.
9A). As an independent confirmation of this interaction, an
antibody against the Flag epitope that marks the dominant-
negative BRG1 was used for immunoprecipitation to show that
the mutant BRG1 interacted with MyoD (data not shown).
Others have also demonstrated that MyoD and Brg1 can be co-
immunoprecipitated from extracts of differentiating cells (54).
Finally, we demonstrate that an antibody against BRG1 can
coimmunoprecipitate Mef2 from MyoD-differentiated cells
(Fig. 9B), while the converse experiment showed that an anti-
body against Mef2 could coimmunoprecipitate Brg1 (Fig. 9C).
An interaction between Mef2 and Brg1 was also detected in
the absence of tetracycline when dominant-negative BRG1 was
expressed. The lighter band likely results from the inhibitory
effect that dominant-negative BRG1 has on Mef2 expression
(see input in Mef2 Western, Fig. 9B). Previously, we reported
that expression of dominant-negative SWI/SNF complexes in-
hibited the expression of Mef2C RNA (17). These results dem-
onstrate that endogenous SWI/SNF enzymes can associate
with endogenous Mef2 in MyoD-differentiated cells.
Taken together, the results indicate that endogenous Brg1
interacts with both Pbx1 and MyoD at the onset of differenti-
ation and with MyoD and Mef2 later during differentiation.
The physical interactions between Brg1 and Pbx1 and between
Brg1 and MyoD support the idea that MyoD is initially tar-
geted to the myogenin promoter via the constitutively bound
Pbx1. Because MyoD and Mef2 have been shown to physically
and functionally interact (42), these data also suggest that
FIG. 8. Pbx1 mediates targeting of Brg1 to the myogenin promoter.
(A) Pbx1 protein levels are unaffected by differentiation (Diff.) or by
the expression of dominant-negative BRG1. Protein extracts from
mock-differentiated cells (	) or cells differentiated with MyoD () in
the presence or absence of tetracycline were run on an SDS-polyacryl-
amide gel and probed with Pbx1, MyoD, or PI 3-kinase antibodies. (B)
Pbx1 association with the myogenin promoter, the p21 promoter, and
the IgH enhancer as measured by ChIP during a time course of dif-
ferentiation induced by MyoD. M indicates samples that were mock
differentiated for 24 h. The linearity of the PCRs was demonstrated by
a twofold titration of input DNAs using the mock-differentiated, plus-
tetracycline (tet) sample. PCR amplification of 1% of the input DNA
is shown. (C) Quantification of Pbx1 association with the myogenin
promoter. Band intensities in each lane were normalized to input.
Induction relative to the plus-tetracycline, mock-differentiated sample
is shown. The data reflect the average of values from two independent
experiments. (D) Endogenous Pbx1 and Brg1 coimmunoprecipitate
from MyoD-differentiated but not mock-differentiated cells. Nuclear
extracts from mock (	) or MyoD-differentiated () cells were immu-
noprecipitated with Brg1 antibody or purified IgG as indicated, and the
immunoprecipitated material was run on an SDS-polyacrylamide gel,
transferred to a membrane, and probed for the presence of Pbx1 and
Brg1. The levels of Pbx1 and Brg1 present in 10% of the input for each
sample are shown.
FIG. 9. Brg1 interacts with MyoD and Mef2 in differentiating cells.
Extracts were prepared from mock-differentiated cells or cells differ-
entiated with MyoD in the presence or absence of tetracycline. (A) Im-
munoprecipitation from nuclear extracts from cells that were mock
differentiated (M) or MyoD differentiated was performed using puri-
fied IgG or antibody against Brg1 at the times indicated. Samples were
run on an SDS-polyacrylamide gel and transferred to a membrane for
Western blotting with MyoD and Brg1 antibodies. Ten percent of the
input for each sample is shown. The samples shown in Fig. 8D and 9A
were from the same time course; the Brg1 input and Brg1 IP bands for
the mock and 0-h time point are the same data that were presented in
Fig. 8D. (B and C) Nuclear extracts were immunoprecipitated from
cells mock (	) or MyoD () differentiated in the presence or absence
of tetracycline for 36 h using purified IgG or antibody against Brg1 or
Mef2 and probed for the presence of Mef2 or Brg1. Confirmation of
Mef2 immunoprecipitation by the Mef2 antibody could not be ob-
tained because the Mef2 band was obscured by the antibody heavy
chains.
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Brg1-based SWI/SNF enzymes may be part of a higher-order
complex containing both MyoD and Mef2 during the activa-
tion of muscle-specific genes. The data suggest that Brg1-based
SWI/SNF enzymes are associated with the myogenin promoter
throughout the differentiation process via protein-protein in-
teractions with several regulatory factors.
DISCUSSION
Stable recruitment of MyoD and Mef2 transcriptional acti-
vators requires functional SWI/SNF enzymes. We found that
Brg1 was localized to the myogenin promoter during differen-
tiation. Stable association of muscle-specific activators with
the myogenin promoter was inhibited by dominant-negative
BRG1, indicating that functional SWI/SNF enzymes are nec-
essary for activator binding. Although in vitro studies using
reconstituted templates and purified factors long ago demon-
strated that SWI/SNF enzymes have the potential to facilitate
activator binding to chromatin (13, 31, 60), there is only one
other direct example of this occurring in mammalian cells. Ma
et al. recently demonstrated that ectopic expression of BRG1
in BRG1-deficient cells stimulated MMP2 transcription and
increased the binding of Sp1 and AP2 to the MMP2 promoter
(35). Temporal analysis of protein binding events at other
mammalian promoters and enhancers has revealed that the
order is gene specific and that SWI/SNF chromatin-remodel-
ing enzymes are generally recruited during the later stages of
the activation process (1, 40, 52, 55, 56). For example, induc-
tion of the beta interferon gene by viral infection results in
ordered binding of an enhancesome complex to a nucleosome-
free region, recruitment of the GCN5 histone acetyltrans-
ferase, association of the Pol II/CBP complex, and subsequent
recruitment of SWI/SNF enzymes. Chromatin remodeling by
SWI/SNF enzymes promotes association of TBP with the
TATA box and transcription initiation (1, 33). During entero-
cyte differentiation, activation of 1 antitrypsin transcription
starts with association of the activator, HNF-1, TBP, and
TFIIB with the promoter followed by Pol II, TFIID compo-
nents, TFIIH, and mediator and then by recruitment of the
activator, HNF-4, CBP/PCAF, and BRM containing SWI/
SNF enzymes (55). We recently demonstrated that during adi-
pocyte differentiation, activation of the PPAR nuclear hor-
mone receptor promoter involves recruitment of SWI/SNF
enzymes to the promoter after binding of the C/EBP activator
and that SWI/SNF-promoter interactions facilitated or stabi-
lized the binding of Pol II-associated general transcription
factors (52). In these and other cases, localization of SWI/SNF
enzymes and chromatin remodeling at the promoter occurred
after activator binding, implying in most of these cases that SWI/
SNF enzymes are needed to complete PIC formation and/or
function. Indeed, early in vitro experiments indicated that SWI/
SNF-mediated remodeling of nucleosomes could permit TBP/
TFIIA binding to nucleosome particles (24). SWI/SNF enzymes
are also required, both in vitro and in vivo, to promote tran-
scriptional elongation of the hsp70 gene (5, 11). Thus, our data
reveal an additional role for SWI/SNF chromatin-remodeling
enzymes in cells and show that SWI/SNF enzymes are needed
at different steps during activation of different genes.
Requirement for MyoD to initiate chromatin remodeling at
the myogenin promoter: a model for SWI/SNF recruitment to
the myogenin promoter. The simplest mechanism for recruit-
ment of chromatin-remodeling enzymes to muscle-specific pro-
moters is recruitment by DNA-bound MyoD. In our study,
there is an apparent paradox: expression of MyoD was neces-
sary for early histone acetylation and SWI/SNF recruitment,
yet ChIP assays showed that MyoD formed a stable, DNA-
bound complex only after these changes occurred. A model to
explain this apparent paradox is that MyoD initially associates
with the myogenin promoter indirectly via interactions with
Pbx1/Meis proteins at a Pbx binding site next to a noncanonical
E box previously identified at 	123/97 of the myogenin pro-
moter. The initiation of myogenin expression in differentiating
cells was recently shown to require the interaction of MyoD
with a DNA-bound complex containing the Pbx homeodomain
protein in the absence of a canonical MyoD binding site, and
protein interactions between MyoD and the Pbx complex were
shown to be necessary for the initial association of MyoD with
the myogenin promoter (4). The interaction of MyoD with
these factors might induce a conformational change in the
Pbx/Meis proteins that permits targeting of Brg1 in differenti-
ating cells. Alternatively, others have demonstrated that Pbx
proteins can interact with HDACs and act to repress transcrip-
tion, and then, upon specific cell signaling, Pbx can become
associated with HATs and promote transcription (51). A sim-
ilar switch potentially could occur upon muscle differentiation,
with the Pbx protein facilitating transcription via interaction
with HATs and/or SWI/SNF enzymes. Indeed, coimmunopre-
cipitation of endogenous Brg1 and endogenous Pbx1 (Fig. 8D)
provides support for models involving targeting of SWI/SNF
components by Pbx/Meis proteins in differentiating cells.
However, given the existing data indicating that both SWI/
SNF and HAT enzymes can also interact with MyoD, we pro-
pose that recruitment of chromatin-remodeling enzymes oc-
curs early during differentiation via interaction with MyoD
bound to the promoter indirectly through the Pbx/Meis pro-
teins. Because the interaction of MyoD is indirect in this sce-
nario, it would not be easily cross-linked at early time points in
our ChIP assays. MyoD is known to interact with p300 and
P/CAF (reviewed in reference 41); targeting these HATs to the
myogenin promoter would result in acetylation of histone tails,
which would help promote the association of SWI/SNF com-
plexes through interactions with the bromodomain present on
the ATPase subunit. The ability of MyoD and Brg1 to stably
associate (Fig. 9) (54), combined with the ability of Brg1 to
interact with Pbx (Fig. 8D), would further promote the asso-
ciation of Brg1-based SWI/SNF enzymes with the myogenin
promoter. Thus, SWI/SNF association with the promoter can be
facilitated by its interactions with acetylated chromatin, with
MyoD, and with Pbx. Subsequent chromatin remodeling by SWI/
SNF would then open the canonical E boxes and the Mef2 site for
factor binding, resulting in stably bound activator complex at
the myogenin promoter that can be detected by ChIP assay. A
schematized version of these events is presented in Fig. 10.
This model is generally consistent with the recent findings of
Simone et al. (54). Using differentiating C2C12 myoblasts, they
demonstrated that MyoD is recruited to the myogenin pro-
moter and induces histone acetylation. Chromatin remodeling
at the promoter required the subsequent recruitment and ac-
tivity of SWI/SNF enzymes, which were dependent on an active
p38 kinase. In that study, MyoD was cross-linked to the myo-
genin promoter prior to chromatin remodeling, which could
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suggest that MyoD is directly bound to the promoter but alter-
natively could indicate that a tighter association exists between
MyoD and the Pbx complex in C2C12 myoblasts than exists in the
MyoD–differentiated fibroblasts, thereby permitting MyoD to
be visualized at the promoter by ChIP at the beginning of the
differentiation process. Both possibilities support a model of
early recruitment of MyoD to the myogenin promoter prior to
acetylation and SWI/SNF recruitment, though the loss of MyoD
binding in the presence of dominant-negative BRG1 (Fig. 5
and 6) and the contribution of Pbx complexes during myogenin
activation in C2C12 cells (4) argue for the latter possibility.
Further experiments will be needed to evaluate the role of
each of the potential interactions occurring at the myogenin
promoter during the activation of gene expression.
MyoD-induced genes show differential requirements for
SWI/SNF enzymes. The expression of the vast majority of
genes measured by the expression array was not altered by the
inhibition of SWI/SNF activity, whereas most genes induced by
MyoD were modestly affected by SWI/SNF inhibition and a
subset of MyoD-regulated genes were highly dependent on
SWI/SNF (see Fig. 1). Our data demonstrate that chromatin
modification and SWI/SNF activity are necessary for MyoD to
form a stable interaction with DNA at the myogenin promoter,
suggesting that chromatin remodeling may be necessary for
MyoD binding at the subset of genes that are highly dependent
on SWI/SNF activity. We suggest that the interaction between
MyoD and Pbx is necessary to initially target MyoD to the
myogenin promoter. It is interesting that there is a significant
overlap between the MyoD-regulated genes that are highly
dependent on SWI/SNF and the subset of genes that require
the domains of MyoD that interact with Pbx for full activation
(unpublished data), suggesting that these domains of MyoD
might be necessary for targeting the protein to multiple differ-
ent promoters as an initial step in gene activation.
Summary. During the establishment of new cell lineages,
changes in chromatin structure become apparent as previously
silent genes are activated. How activators initially gain access
to their binding sites within condensed chromatin structure has
been a topic of intense investigation. In some cases, such as
during differentiation of liver cells, the HNF3 homeodomain
protein can bind to nucleosomal DNA and disrupt nucleo-
somal structure in the absence of ATP-dependent chroma-
tin-remodeling enzymes (10). In other cases, gene-specific
activators recruit chromatin-remodeling enzymes to specific
promoters (12). Our results suggest that during muscle differ-
entiation, muscle-specific activators may both recruit and re-
quire chromatin-remodeling activities for stable binding to the
regulatory regions of muscle-specific genes.
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